Clinical characteristics at the time of initiation of therapy in 587 patients with symptomatic Waldenström macroglobulinemia
| Characteristic . | Median (SD) . | No. (%) . |
|---|---|---|
| Patients | 587 | |
| Age, y | 67 (11) | — |
| Hemoglobin, g/dL | 10.4 (2.1) | — |
| Platelet count, ×109/L | 210 (119) | — |
| Absolute neutrophil count, ×109/L | 3.35 (2.6) | — |
| Serum albumin, g/dL | 3.7 (1.6) | — |
| Serum monoclonal protein, g/dL | 3.2 (2.1) | — |
| Serum β2-microglobulin, mg/L | 3.2 (2.3) | — |
| Bulky adenopathy | — | 117 (20) |
| Splenomegaly | — | 94 (16) |
| Hepatomegaly | — | 62 (11) |
| Criteria for treatment initiation | ||
| Cytopenia | — | 300 (51) |
| Single criterion/in association | — | 81/219 |
| Organomegaly | — | 207 (35) |
| Single criterion/in association | — | 0/207 |
| Hyperviscosity | — | 183 (31) |
| Single criterion/in association | — | 47/136 |
| Constitutional symptoms | — | 255 (44) |
| Single criterion/in association | — | 42/213 |
| IgM-related symptoms | — | 77 (13) |
| Single criterion/in association | — | 20/57 |
| Treatment regimen | ||
| Alkylating agent | — | 369 (62.8) |
| Fludarabine alone | — | 189 (32.2) |
| Fludarabine plus alkylating agent | — | 6 (1) |
| Rituximab | — | 23 (4) |
| Characteristic . | Median (SD) . | No. (%) . |
|---|---|---|
| Patients | 587 | |
| Age, y | 67 (11) | — |
| Hemoglobin, g/dL | 10.4 (2.1) | — |
| Platelet count, ×109/L | 210 (119) | — |
| Absolute neutrophil count, ×109/L | 3.35 (2.6) | — |
| Serum albumin, g/dL | 3.7 (1.6) | — |
| Serum monoclonal protein, g/dL | 3.2 (2.1) | — |
| Serum β2-microglobulin, mg/L | 3.2 (2.3) | — |
| Bulky adenopathy | — | 117 (20) |
| Splenomegaly | — | 94 (16) |
| Hepatomegaly | — | 62 (11) |
| Criteria for treatment initiation | ||
| Cytopenia | — | 300 (51) |
| Single criterion/in association | — | 81/219 |
| Organomegaly | — | 207 (35) |
| Single criterion/in association | — | 0/207 |
| Hyperviscosity | — | 183 (31) |
| Single criterion/in association | — | 47/136 |
| Constitutional symptoms | — | 255 (44) |
| Single criterion/in association | — | 42/213 |
| IgM-related symptoms | — | 77 (13) |
| Single criterion/in association | — | 20/57 |
| Treatment regimen | ||
| Alkylating agent | — | 369 (62.8) |
| Fludarabine alone | — | 189 (32.2) |
| Fludarabine plus alkylating agent | — | 6 (1) |
| Rituximab | — | 23 (4) |
In association means that at least 1 of the other criteria for treatment initiation was present.